Close Menu

NEW YORK (GenomeWeb) – Biocept said today that it has begun a clinical research collaboration with the University of Texas Southwestern Medical Center focused on non-small cell lung cancer.

The company will work with a team led by UT Southwestern researcher Saad Khan to evaluate its Target Selector platform for rapid detection of ALK mutations in patients with NSCLC. Tests will be performed both at baseline and longitudinally to measure treatment response and early signs of resistance.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jul
23

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.